^
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive
    :
    A1
    Merck (MSD) Press Release - 6d
    HER-2 overexpression + PTEN deletion
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Resistant
    :
    C3
    Sci Rep - 2wk
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive
    :
    A1
    FDA - 3wk
    FGFR2b overexpression + HER2 negative
    Gastroesophageal Junction Adenocarcinoma
    FPA-144
    Sensitive
    :
    B
    Amgen Press Release - 3wk
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive
    :
    A1
    PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Herzuma (trastuzumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    trifluridine/tipiracil
    Sensitive
    :
    A1
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    ramucirumab
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Zercepac (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A1
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + capecitabine
    Sensitive
    :
    A2
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    DOF
    Sensitive
    :
    A2
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TCF
    Sensitive
    :
    A2
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    FP
    Sensitive
    :
    A2
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    CaT
    Sensitive
    :
    A2
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    CAPOX
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES